Arcturus Therapeutics (ARCT)
US Market

Arcturus Therapeutics (ARCT) Income Statement


Arcturus Therapeutics Income Statement

Last quarter (Q1 2023), Arcturus Therapeutics's total revenue was $80.28M, an increase of 1430.99% from the same quarter last year. In Q1, Arcturus Therapeutics's net income was $50.75M. See Arcturus Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 281.04M$ 206.00M$ 12.36M$ 9.54M$ 20.79M$ 15.75M
Cost of Revenue
Gross Profit
$ 240.58M$ 206.00M----
Operating Expense
$ 126.05M$ -193.82M$ 215.21M$ 81.06M$ 46.30M$ 37.56M
Operating Income
$ 77.31M$ 12.18M$ -202.85M$ -71.52M$ -25.51M$ -21.81M
Net Non Operating Interest Income Expense
$ -1.38M$ 900.00K$ -1.92M$ -361.00K$ -446.00K$ 328.00K
Other Income Expense
$ -34.51M$ 935.00K$ 1.10M$ -263.00K$ -32.00K$ -302.00K
Pretax Income
$ 112.67M$ 10.64M$ -203.67M$ -72.15M$ -25.99M$ -21.79M
Tax Provision
$ 1.40M$ 1.29M---$ 0.00
Earnings From Equity Interest Net Of Tax
-$ -515.00K----
Net Income Common Stockholders
$ 111.27M$ 9.35M$ -203.67M$ -72.15M$ -25.99M$ -21.79M
Basic EPS
$ 2.26$ 0.35$ -7.74$ -3.55$ -2.15$ -2.16
Diluted EPS
$ 4.16$ 0.35$ -7.74$ -3.55$ -2.15$ -2.16
Basic Average Shares
$ 79.36M$ 26.45M$ 26.32M$ 20.30M$ 12.07M$ 10.07M
Diluted Average Shares
$ 80.01M$ 27.09M$ 26.32M$ 20.30M$ 12.07M$ 10.07M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 126.05M$ -193.82M$ 215.21M$ 81.06M$ 46.30M$ 37.56M
Net Income From Continuing And Discontinued Operation
$ 111.27M$ 9.35M$ -203.67M$ -72.15M$ -25.99M$ -21.79M
Normalized Income
$ -59.91M-$ -204.26M$ -72.15M$ -25.99M$ -21.79M
Interest Expense
$ 1.49M-$ 2.67M$ 831.00K$ 854.00K$ 186.00K
$ 114.66M$ 9.74M$ -201.00M$ -71.32M$ -25.14M$ -21.60M
$ 113.92M$ 8.24M$ -199.81M$ -70.44M$ -24.45M$ -21.02M
Currency in USD

Arcturus Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis